BTK and diffuse large B-cell lymphoma: Indeed, a number of different new drugs including lenalidomide, some proteasome inhibitors, and the BTK inhibitor ibrutinib (PCI-32765) have recently shown promising results, especially in non-GCB/ABC DLBCL patients [7, 46–49].